- Home
- CHRS vs DMRC Comparison
CHRS vs DMRC Comparison
Compare CHRS & DMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- DMRC
- Stock Information
- Founded
- CHRS 2010
- DMRC 2008
- Country
- CHRS United States
- DMRC United States
- Employees
- CHRS N/A
- DMRC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- DMRC EDP Services
- Sector
- CHRS Health Care
- DMRC Technology
- Exchange
- CHRS Nasdaq
- DMRC Nasdaq
- Market Cap
- CHRS 186.0M
- DMRC 158.2M
- IPO Year
- CHRS 2014
- DMRC N/A
- Fundamental
- Price
- CHRS $1.11
- DMRC $6.69
- Analyst Decision
- CHRS Strong Buy
- DMRC Strong Buy
- Analyst Count
- CHRS 4
- DMRC 1
- Target Price
- CHRS $4.51
- DMRC $20.00
- AVG Volume (30 Days)
- CHRS 1.4M
- DMRC 173.1K
- Earning Date
- CHRS 11-06-2025
- DMRC 10-30-2025
- Dividend Yield
- CHRS N/A
- DMRC N/A
- EPS Growth
- CHRS N/A
- DMRC N/A
- EPS
- CHRS 1.34
- DMRC N/A
- Revenue
- CHRS $277,728,000.00
- DMRC $33,663,000.00
- Revenue This Year
- CHRS N/A
- DMRC N/A
- Revenue Next Year
- CHRS $109.48
- DMRC $7.63
- P/E Ratio
- CHRS $0.82
- DMRC N/A
- Revenue Growth
- CHRS 152.07
- DMRC N/A
- 52 Week Low
- CHRS $0.71
- DMRC $6.60
- 52 Week High
- CHRS $2.43
- DMRC $48.32
- Technical
- Relative Strength Index (RSI)
- CHRS 31.08
- DMRC 26.81
- Support Level
- CHRS $1.09
- DMRC $6.80
- Resistance Level
- CHRS $1.25
- DMRC $7.46
- Average True Range (ATR)
- CHRS 0.13
- DMRC 0.57
- MACD
- CHRS -0.04
- DMRC -0.20
- Stochastic Oscillator
- CHRS 0.81
- DMRC 0.13
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.